Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats

Figure 1 The colonic mucosal mRNA expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in control, AE-941 and ulcerative colitis model groups at different timepoints. Expression of matrix metalloproteinases (MMP)-2 and MMP-9 in the colonic mucosa was significantly higher in the ulcerative colitis model group compared to the control group (P < 0.05). On days 21 and 56, the two index values in the AE-941 treatment group were significantly less than that of the model group (P < 0.05). M: Marker; C: Control group; AE: AE-941 group; UC: UC model group.

Figure 2 Colonic mucosal matrix metalloproteinase-2 and -9 protein expression in control, AE-941, and ulcerative colitis model groups at different timepoints. The expression of matrix metalloproteinases (MMP)-2 (A) and MMP-9 (B) protein in the colonic mucosa of the ulcerative colitis model group was significantly higher than in the control group (P < 0.05). By days 21 and 56 expression of MMP-2 and MMP-9 in the AE-941 treatment group was significantly less than in the model group (P < 0.05).